Cargando…
Cell based therapies in Parkinson’s Disease
Parkinson’s disease (PD) is the second most common neurodegenerative disorder after Alzheimer’s disease. It is characterized by bradykinesia, hypokinesia/ akinesia, rigidity, tremor, and postural instability, caused by dopaminergic (DA) striatal denervation. The prevalence of PD increases from 50 ye...
Autores principales: | Behari, Madhuri, Singhal, Kapil Kumar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Indian Academy of Neurosciences
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4117039/ https://www.ncbi.nlm.nih.gov/pubmed/25205926 http://dx.doi.org/10.5214/ans.0972.7531.1118209 |
Ejemplares similares
-
Gene-based therapy of Parkinson’s Disease: Translation from animal model to human clinical trial employing convection enhanced delivery
por: Miranpuri, Gurwattan S., et al.
Publicado: (2012) -
A systematic review and meta‐ethnographic synthesis of Mindfulness‐based Cognitive Therapy for people with major depression
por: Williams, Kate, et al.
Publicado: (2022) -
Glycosphingolipid metabolism and its role in ageing and Parkinson’s disease
por: Wallom, Kerri-Lee, et al.
Publicado: (2021) -
Human Neural Stem Cell Therapy for Chronic Ischemic Stroke: Charting Progress from Laboratory to Patients
por: Sinden, John D., et al.
Publicado: (2017) -
COVID-19: inflammatory responses, structure-based drug design and potential therapeutics
por: Tripathi, Neetu, et al.
Publicado: (2021)